Allergan, Chase deal

Allergan acquired Chase for $125 million up front, plus undisclosed milestones tied to the company's CPC-201 to treat Alzheimer's disease. Allergan said it plans to begin a Phase III trial of CPC-201 next year. Chase pairs complementary molecules with marketed AD drugs to improve the drugs' side effect profiles. CPC-201 combines marketed drug Aricept donepezil, a reversible acetylcholinesterase (AChE) inhibitor, with solifenacin, a peripherally acting cholinergic blocker...